Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Zosano Pharma reports Q3 EPS (11c), consensus (10c) » 16:06
11/13/20
11/13
16:06
11/13/20
16:06
ZSAN

Zosano Pharma

$0.46 /

-0.0004 (-0.09%)

As of September 30, cash…

As of September 30, cash and cash equivalents were $43.6M as compared with $6.3M as of December 31, 2019.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$0.46 /

-0.0004 (-0.09%)

ZSAN Zosano Pharma
$0.46 /

-0.0004 (-0.09%)

10/22/20 BTIG
Zosano Pharma price target lowered to $2 from $7 at BTIG
10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
ZSAN Zosano Pharma
$0.46 /

-0.0004 (-0.09%)

  • 01
    Sep
ZSAN Zosano Pharma
$0.46 /

-0.0004 (-0.09%)

Over a month ago
Recommendations
Zosano Pharma price target lowered to $2 from $7 at BTIG » 06:24
10/22/20
10/22
06:24
10/22/20
06:24
ZSAN

Zosano Pharma

$0.44 /

-0.1673 (-27.35%)

BTIG analyst Robert…

BTIG analyst Robert Hazlett lowered the firm's price target on Zosano Pharma to $2 from $7 and keeps a Buy rating on the shares. The analyst cites the receipt of a CRL from FDA, following a recent discipline review letter regarding the NDA for Qtrypta - its transdermal microneedle system form of zolmitriptan in development for acute migraine - as well as the FDA questions regarding unexpectedly high plasma concentrations of zolmitriptan in five subjects from two pharmacokinetic studies. Hazlett notes that additional product quality validation data appears necessary, but he believes that these items can be resolved with modest additional PK and bioequivalence work.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$0.44 /

-0.1673 (-27.35%)

ZSAN Zosano Pharma
$0.44 /

-0.1673 (-27.35%)

10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
ZSAN Zosano Pharma
$0.44 /

-0.1673 (-27.35%)

  • 01
    Sep
ZSAN Zosano Pharma
$0.44 /

-0.1673 (-27.35%)

Hot Stocks
Zosano Pharma says FDA recommends repeat bioequivalence study for Qtrypta » 08:34
10/21/20
10/21
08:34
10/21/20
08:34
ZSAN

Zosano Pharma

$0.61 /

-0.0284 (-4.44%)

Zosano Pharma announced…

Zosano Pharma announced that it has received a complete response letter from the U.S. Food and Drug Administration in connection with the Qtrypta 505(b)(2) New Drug Application. The CRL cited inconsistent zolmitriptan exposure levels observed across clinical pharmacology studies, which had been previously identified in the FDA's discipline review letter in September. Specifically, the CRL noted differences in zolmitriptan exposures observed between subjects receiving different lots of Qtrypta in the company's trials and inadequate pharmacokinetic bridging between the lots that made interpretation of some safety data unclear. The CRL referenced unexpected high plasma concentrations of zolmitriptan observed in five study subjects enrolled in the company's pharmacokinetic studies. The FDA recommended that the company conduct a repeat bioequivalence study between three of the lots used during development. The NDA included data on a total of 774 subjects across 5 trials who were administered or dosed with Qtrypta. The CRL noted that additional product quality validation data, which were planned to be submitted following approval, if received, were required to be submitted with the application. In addition, the CRL mentioned that due to U.S. Government and/or Agency-wide restrictions on travel, inspections of Zosano's contract manufacturing facilities were not able to be conducted but would be required before the application may be approved. Zosano will request a Type A meeting with the FDA to discuss strategies to address the FDA's comments.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$0.61 /

-0.0284 (-4.44%)

ZSAN Zosano Pharma
$0.61 /

-0.0284 (-4.44%)

10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
ZSAN Zosano Pharma
$0.61 /

-0.0284 (-4.44%)

  • 01
    Sep
ZSAN Zosano Pharma
$0.61 /

-0.0284 (-4.44%)

Recommendations
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright » 06:15
10/02/20
10/02
06:15
10/02/20
06:15
ZSAN

Zosano Pharma

$0.70 /

-0.9201 (-56.80%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Zosano Pharma to $2.50 from $4 and reiterates a Buy rating on the shares. The discipline review letter from the FDA will likely delay approval of Qtrypta, Selvaraju tells investors in a research note.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$0.70 /

-0.9201 (-56.80%)

ZSAN Zosano Pharma
$0.70 /

-0.9201 (-56.80%)

09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
11/15/19 Cantor Fitzgerald
Zosano Pharma price target lowered to $6 from $12 at Cantor Fitzgerald
ZSAN Zosano Pharma
$0.70 /

-0.9201 (-56.80%)

  • 01
    Sep
ZSAN Zosano Pharma
$0.70 /

-0.9201 (-56.80%)

On The Fly
Fly Intel: Pre-market Movers » 09:01
10/01/20
10/01
09:01
10/01/20
09:01
PLBY

Playboy

$0.00 /

+ (+0.00%)

, AEL

American Equity

$22.02 /

+0.13 (+0.59%)

, MCAC

Mountain Crest Acquisition

$10.12 /

+0.01 (+0.10%)

, ASAN

Asana

$29.42 /

+ (+0.00%)

, CPE

Callon Petroleum

$4.82 /

-0.11 (-2.23%)

, SAIL

SailPoint

$39.61 /

+1.17 (+3.04%)

, BBBY

Bed Bath & Beyond

$14.98 /

+0.48 (+3.31%)

, ZSAN

Zosano Pharma

$1.62 /

-0.005 (-0.31%)

, SELB

Selecta Biosciences

$2.47 /

-0.08 (-3.14%)

, LOGC

LogicBio Therapeutics

$9.07 /

-0.35 (-3.72%)

, PAR

Par Technology

$40.41 /

-3.86 (-8.72%)

, BEAM

Beam Therapeutics

$24.63 /

-0.05 (-0.20%)

Check out this morning's…

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

SELB Selecta Biosciences
$2.47 /

-0.08 (-3.14%)

SAIL SailPoint
$39.61 /

+1.17 (+3.04%)

PAR Par Technology
$40.41 /

-3.86 (-8.72%)

MCAC Mountain Crest Acquisition
$10.12 /

+0.01 (+0.10%)

LOGC LogicBio Therapeutics
$9.07 /

-0.35 (-3.72%)

CPE Callon Petroleum
$4.82 /

-0.11 (-2.23%)

BEAM Beam Therapeutics
$24.63 /

-0.05 (-0.20%)

BBBY Bed Bath & Beyond
$14.98 /

+0.48 (+3.31%)

AEL American Equity
$22.02 /

+0.13 (+0.59%)

PLBY Playboy
$0.00 /

+ (+0.00%)

AEL American Equity
$22.02 /

+0.13 (+0.59%)

08/19/20 Raymond James
American Equity downgraded at Raymond James on lack of near-term catalysts
08/19/20 Raymond James
American Equity downgraded to Market Perform from Outperform at Raymond James
08/04/20 Morgan Stanley
American Equity initiated with an Equal Weight at Morgan Stanley
07/09/20 B. Riley Securities
American Equity price target raised to $23 from $19 at B. Riley FBR
MCAC Mountain Crest Acquisition
$10.12 /

+0.01 (+0.10%)

ASAN Asana
$29.42 /

+ (+0.00%)

CPE Callon Petroleum
$4.82 /

-0.11 (-2.23%)

09/25/20
Fly Intel: Top five analyst initiations
09/25/20 Wells Fargo
Callon Petroleum initiated with an Underweight at Wells Fargo
05/28/20
Fly Intel: Top five analyst initiations
05/28/20 MKM Partners
Callon Petroleum initiated with a Buy at MKM Partners
SAIL SailPoint
$39.61 /

+1.17 (+3.04%)

10/01/20 Morgan Stanley
SailPoint upgraded to Overweight from Equal Weight at Morgan Stanley
09/09/20 Loop Capital
SailPoint initiated with a Hold at Loop Capital
09/08/20 Loop Capital
SailPoint initiated with a Hold at Loop Capital
08/28/20 Canaccord
SailPoint price target raised to $47 from $39 at Canaccord
BBBY Bed Bath & Beyond
$14.98 /

+0.48 (+3.31%)

09/24/20
Fly Intel: Top five analyst upgrades
09/24/20 Baird
Baird upgrades Bed Bath & Beyond to Outperform on turnaround potential
09/24/20 Baird
Bed Bath & Beyond upgraded to Outperform from Neutral at Baird
09/10/20 Wedbush
Bed Bath & Beyond added to Best Ideas List, price raised to $18 at Wedbush
ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
11/15/19 Cantor Fitzgerald
Zosano Pharma price target lowered to $6 from $12 at Cantor Fitzgerald
SELB Selecta Biosciences
$2.47 /

-0.08 (-3.14%)

10/01/20 Mizuho
Selecta downgraded to Neutral with $2.50 target at Mizuho
10/01/20 William Blair
Selecta downgraded to Market Perform from Outperform at William Blair
10/01/20 Mizuho
Selecta Biosciences downgraded to Neutral from Buy at Mizuho
06/12/20
Selecta Biosciences downgraded to Hold from Buy at Stifel
LOGC LogicBio Therapeutics
$9.07 /

-0.35 (-3.72%)

01/10/20 Roth Capital
LogicBio reported 'two wins' with updates, says Roth Capital
PAR Par Technology
$40.41 /

-3.86 (-8.72%)

09/16/20 Sidoti
Par Technology downgraded to Neutral from Buy at Sidoti
09/15/20 BTIG
Par Technology price target raised to $50 from $43 at BTIG
09/14/20 BTIG
Par Technology price target raised to $50 from $43 at BTIG
06/22/20 Craig-Hallum
Par Technology price target raised to $40 from $30 at Craig-Hallum
BEAM Beam Therapeutics
$24.63 /

-0.05 (-0.20%)

08/05/20
Fly Intel: Top five analyst initiations
08/05/20 William Blair
Beam Therapeutics initiated with an Outperform at William Blair
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

SELB Selecta Biosciences
$2.47 /

-0.08 (-3.14%)

SAIL SailPoint
$39.61 /

+1.17 (+3.04%)

PAR Par Technology
$40.41 /

-3.86 (-8.72%)

LOGC LogicBio Therapeutics
$9.07 /

-0.35 (-3.72%)

CPE Callon Petroleum
$4.82 /

-0.11 (-2.23%)

BEAM Beam Therapeutics
$24.63 /

-0.05 (-0.20%)

BBBY Bed Bath & Beyond
$14.98 /

+0.48 (+3.31%)

AEL American Equity
$22.02 /

+0.13 (+0.59%)

  • 01
    Oct
  • 01
    Oct
  • 01
    Oct
  • 01
    Sep
  • 06
    Feb
MCAC Mountain Crest Acquisition
$10.12 /

+0.01 (+0.10%)

CPE Callon Petroleum
$4.82 /

-0.11 (-2.23%)

BEAM Beam Therapeutics
$24.63 /

-0.05 (-0.20%)

BBBY Bed Bath & Beyond
$14.98 /

+0.48 (+3.31%)

AEL American Equity
$22.02 /

+0.13 (+0.59%)

ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

SAIL SailPoint
$39.61 /

+1.17 (+3.04%)

CPE Callon Petroleum
$4.82 /

-0.11 (-2.23%)

BEAM Beam Therapeutics
$24.63 /

-0.05 (-0.20%)

BBBY Bed Bath & Beyond
$14.98 /

+0.48 (+3.31%)

ASAN Asana
$29.42 /

+ (+0.00%)

CPE Callon Petroleum
$4.82 /

-0.11 (-2.23%)

BBBY Bed Bath & Beyond
$14.98 /

+0.48 (+3.31%)

Hot Stocks
Zosano receives discipline review letter from FDA regarding Qtrypta NDA » 17:43
09/30/20
09/30
17:43
09/30/20
17:43
ZSAN

Zosano Pharma

$1.62 /

-0.005 (-0.31%)

Zosano Pharma Corporation…

Zosano Pharma Corporation announced that it has received a discipline review letter, or DRL, from the FDA in connection with the Qtrypta New Drug Application, or NDA. A DRL is used by the FDA to convey preliminary comments on deficiencies identified during the NDA review with respect to a particular review discipline. The DRL described two concerns with respect to the clinical pharmacology section of the NDA. First, the FDA raised questions regarding unexpected high plasma concentrations of zolmitriptan observed in five study subjects from two pharmacokinetic studies and how the data from these subjects affect the overall clinical pharmacology section of the application. Second, the FDA raised questions regarding differences in zolmitriptan exposures observed between subjects receiving different lots of Qtrypta in the company's clinical trials. Although a DRL reflects preliminary comments that are subject to change, and does not reflect the FDA's final decision on the NDA, approval of Qtrypta by the PDUFA goal date of October 20, 2020 is not expected given the letter. "We are disappointed in this notification and are in the process of evaluating and addressing FDA's comments," said Steven Lo, CEO of Zosano. "We believe Qtrypta represents an attractive therapeutic alternative for patients suffering from migraines and look forward to working with FDA through the NDA review process."

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
11/15/19 Cantor Fitzgerald
Zosano Pharma price target lowered to $6 from $12 at Cantor Fitzgerald
ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

  • 01
    Sep
ZSAN Zosano Pharma
$1.62 /

-0.005 (-0.31%)

Recommendations
Satsuma setback a positive for Zosano Pharma, says BTIG » 09:51
09/14/20
09/14
09:51
09/14/20
09:51
ZSAN

Zosano Pharma

$1.56 /

+0.055 (+3.65%)

, STSA

Satsuma Pharmaceuticals

$4.94 /

+0.08 (+1.65%)

BTIG analyst Robert…

BTIG analyst Robert Hazlett noted that Satsuma (STSA) recently announced that its Phase 3 EMERGE efficacy trial of its dry powder nasal formulation of dihydroergotamine mesylate for the acute treatment of migraine did not show statistical significance in either of its two primary endpoints. He views this as a positive for Zosano Pharma (ZSAN) as it potentially removes a competitor in the acute migraine space and it underscores the strength of the Phase 3 results for Zosano's own acute migraine therapy, Qtrypta. Hazlett has a Buy rating and $7 price target on Zosano shares.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.56 /

+0.055 (+3.65%)

STSA Satsuma Pharmaceuticals
$4.94 /

+0.08 (+1.65%)

ZSAN Zosano Pharma
$1.56 /

+0.055 (+3.65%)

04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
11/15/19 Cantor Fitzgerald
Zosano Pharma price target lowered to $6 from $12 at Cantor Fitzgerald
STSA Satsuma Pharmaceuticals
$4.94 /

+0.08 (+1.65%)

09/11/20
Fly Intel: Top five analyst downgrades
09/11/20 SVB Leerink
Satsuma Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
09/11/20 Credit Suisse
Satsuma downgraded to Underperform from Outperform at Credit Suisse
09/11/20 Mizuho
Satsuma downgraded to Neutral with $4 target at Mizuho
ZSAN Zosano Pharma
$1.56 /

+0.055 (+3.65%)

STSA Satsuma Pharmaceuticals
$4.94 /

+0.08 (+1.65%)

  • 01
    Sep
ZSAN Zosano Pharma
$1.56 /

+0.055 (+3.65%)

STSA Satsuma Pharmaceuticals
$4.94 /

+0.08 (+1.65%)

Syndicate
Zosano Pharma 15.94M share Spot Secondary priced around $1.30 per share » 09:14
09/01/20
09/01
09:14
09/01/20
09:14
ZSAN

Zosano Pharma

$1.64 /

+0.03 (+1.86%)

Zosano Pharma announced…

Zosano Pharma announced the pricing of an underwritten public offering of 15,937,130 shares of its common stock for gross proceeds of approximately $20.8M. BTIG is acting as sole book running manager for the offering.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
11/15/19 Cantor Fitzgerald
Zosano Pharma price target lowered to $6 from $12 at Cantor Fitzgerald
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

  • 01
    Sep
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

On The Fly
Fly Intel: Pre-market Movers » 09:00
09/01/20
09/01
09:00
09/01/20
09:00
ATNX

Athenex

$11.47 /

+0.74 (+6.90%)

, KODK

Eastman Kodak

$5.98 /

-0.055 (-0.91%)

, GOGO

Gogo

$5.15 /

+0.16 (+3.21%)

, BBW

Build-A-Bear

$2.58 /

+0.21 (+8.86%)

, WSG

Wanda Sports

$2.15 /

+0.07 (+3.37%)

, ZM

Zoom Video

$325.24 /

+26.28 (+8.79%)

, DRI

Darden

$86.83 /

-2.95 (-3.29%)

, ZSAN

Zosano Pharma

$1.64 /

+0.03 (+1.86%)

, EAT

Brinker

$45.04 /

-0.59 (-1.29%)

, FINV

FinVolution Group

$1.91 /

-0.18 (-8.61%)

Check out this morning's…

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

WSG Wanda Sports
$2.15 /

+0.07 (+3.37%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

FINV FinVolution Group
$1.91 /

-0.18 (-8.61%)

EAT Brinker
$45.04 /

-0.59 (-1.29%)

DRI Darden
$86.83 /

-2.95 (-3.29%)

BBW Build-A-Bear
$2.58 /

+0.21 (+8.86%)

ATNX Athenex
$11.47 /

+0.74 (+6.90%)

ATNX Athenex
$11.47 /

+0.74 (+6.90%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 Truist
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

08/27/20 Roth Capital
Gogo's CA could fetch up to $2+ a share, says Roth Capital
08/11/20 Northland
Gogo exploring CA unit sale highlights 'turbulent position,' says Northland
08/10/20 Roth Capital
Gogo price target raised to $8 from $7 at Roth Capital
07/07/20 Roth Capital
Roth Capital still bullish on Gogo, says new 3k foot floor highlights BA value
BBW Build-A-Bear
$2.58 /

+0.21 (+8.86%)

12/13/19 Jefferies
Removal, delay of China tariffs give 'reprieve' to toy companies, says Jefferies
WSG Wanda Sports
$2.15 /

+0.07 (+3.37%)

06/10/20 Deutsche Bank
Wanda Sports price target raised to $8 from $7 at Deutsche Bank
12/23/19 Deutsche Bank
Wanda Sport shares offer 'attractive value,' says Deutsche Bank
12/12/19 Loop Capital
Wanda Sports downgraded to Hold from Buy at Loop Capital
12/12/19 Loop Capital
Wanda Sports downgraded to Hold from Buy at Loop Capital
ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

09/01/20 JPMorgan
Zoom Video price target raised to $425 from $220 at JPMorgan
09/01/20 Needham
Zoom Video price target raised to $440 from $230 at Needham
09/01/20 DA Davidson
Zoom Video price target raised to $460 from $240 at DA Davidson
09/01/20 Baird
Zoom Video price target raised to $465 from $300 at Baird
DRI Darden
$86.83 /

-2.95 (-3.29%)

09/01/20 Raymond James
Darden downgraded to Outperform from Strong Buy at Raymond James
08/27/20 Stephens
Texas Roadhouse downgraded to Equal Weight from Overweight at Stephens
08/27/20 Stephens
Stephens resumes Darden at Overweight, names Best Idea
08/19/20
Fly Intel: Top five analyst downgrades
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
11/15/19 Cantor Fitzgerald
Zosano Pharma price target lowered to $6 from $12 at Cantor Fitzgerald
EAT Brinker
$45.04 /

-0.59 (-1.29%)

09/01/20 Raymond James
Brinker downgraded to Market Perform from Outperform at Raymond James
08/28/20
Fly Intel: Top five analyst upgrades
08/28/20 MKM Partners
Brinker price target raised to $46 from $38 at MKM Partners
08/28/20 Morgan Stanley
Morgan Stanley upgrades Brinker to Equal Weight on sales and margin performance
FINV FinVolution Group
$1.91 /

-0.18 (-8.61%)

09/01/20 Citi
FinVolution Group downgraded to Neutral from Buy at Citi
09/01/20 UBS
FinVolution Group downgraded to Neutral from Buy at UBS
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

WSG Wanda Sports
$2.15 /

+0.07 (+3.37%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

EAT Brinker
$45.04 /

-0.59 (-1.29%)

DRI Darden
$86.83 /

-2.95 (-3.29%)

BBW Build-A-Bear
$2.58 /

+0.21 (+8.86%)

ATNX Athenex
$11.47 /

+0.74 (+6.90%)

  • 01
    Sep
  • 07
    May
  • 21
    Apr
ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

DRI Darden
$86.83 /

-2.95 (-3.29%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

EAT Brinker
$45.04 /

-0.59 (-1.29%)

DRI Darden
$86.83 /

-2.95 (-3.29%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

EAT Brinker
$45.04 /

-0.59 (-1.29%)

DRI Darden
$86.83 /

-2.95 (-3.29%)

On The Fly
Fly Intel: After-Hours Movers » 19:01
08/31/20
08/31
19:01
08/31/20
19:01
ZM

Zoom Video

$325.24 /

+26.28 (+8.79%)

, RXT

Rackspace Technology

$21.35 /

+2.045 (+10.59%)

, KODK

Eastman Kodak

$5.98 /

-0.055 (-0.91%)

, GOGO

Gogo

$5.15 /

+0.16 (+3.21%)

, TTOO

T2 Biosystems

$1.56 /

+0.015 (+0.97%)

, NPTN

NeoPhotonics

$6.67 /

-0.245 (-3.55%)

, SITM

SiTime

$66.03 /

-2.1 (-3.08%)

, COHU

Cohu

$17.19 /

-0.81 (-4.50%)

, SCSC

Scansource

$24.68 /

+0.03 (+0.12%)

, ZSAN

Zosano Pharma

$1.64 /

+0.03 (+1.86%)

Check out this evening's…

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

TTOO T2 Biosystems
$1.56 /

+0.015 (+0.97%)

SITM SiTime
$66.03 /

-2.1 (-3.08%)

SCSC Scansource
$24.68 /

+0.03 (+0.12%)

RXT Rackspace Technology
$21.35 /

+2.045 (+10.59%)

NPTN NeoPhotonics
$6.67 /

-0.245 (-3.55%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

08/25/20 Baird
Zoom Video inks signature phone win with Cardinal, says Baird
08/20/20 Morgan Stanley
Zoom Video price target raised to $240 from $190 at Morgan Stanley
08/18/20 RBC Capital
Zoom Video price target raised to $300 from $250 at RBC Capital
07/24/20 Wolfe Research
Zoom Video initiated with a Peer Perform at Wolfe Research
RXT Rackspace Technology
$21.35 /

+2.045 (+10.59%)

08/31/20 Evercore ISI
Rackspace Technology initiated with an Outperform at Evercore ISI
08/31/20 JPMorgan
Rackspace Technology initiated with an Overweight at JPMorgan
08/31/20 Deutsche Bank
Rackspace Technology initiated with a Buy at Deutsche Bank
08/31/20 RBC Capital
Rackspace Technology initiated with an Outperform at RBC Capital
KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

08/27/20 Roth Capital
Gogo's CA could fetch up to $2+ a share, says Roth Capital
08/11/20 Northland
Gogo exploring CA unit sale highlights 'turbulent position,' says Northland
08/10/20 Roth Capital
Gogo price target raised to $8 from $7 at Roth Capital
07/07/20 Roth Capital
Roth Capital still bullish on Gogo, says new 3k foot floor highlights BA value
TTOO T2 Biosystems
$1.56 /

+0.015 (+0.97%)

08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
07/16/20 Canaccord
T2 Biosystems price target raised to $4 from $3 at Canaccord
02/06/20 JonesTrading
T2 Biosystems upgraded to Buy from Hold at JonesTrading
01/23/20 Alliance Global Partners
T2 Biosystems upgraded to Buy from Neutral at Alliance Global Partners
NPTN NeoPhotonics
$6.67 /

-0.245 (-3.55%)

08/31/20
Fly Intel: Top five analyst downgrades
08/31/20 Needham
Needham downgrades NeoPhotonics to Hold on new Commerce rules
08/31/20 Needham
NeoPhotonics downgraded to Hold from Buy at Needham
08/25/20 Raymond James
NeoPhotonics downgraded at Raymond James after assessing Huawei risk
SITM SiTime
$66.03 /

-2.1 (-3.08%)

08/06/20 Roth Capital
SiTime price target raised to $75 from $60 at Roth Capital
08/06/20 Barclays
SiTime price target raised to $75 from $50 at Barclays
07/07/20 Needham
SiTime price target raised to $55 from $40 at Needham
06/30/20
Fly Intel: Top five analyst initiations
COHU Cohu
$17.19 /

-0.81 (-4.50%)

08/31/20 B. Riley Securities
B. Riley FBR sees 44% upside in Cohu shares after recent pullback
07/28/20 Deutsche Bank
Cohu price target raised to $21 from $18 at Deutsche Bank
06/16/20 Needham
Cohu initiated with a Buy at Needham
05/21/20 B. Riley Securities
Cohu estimates look 'increasingly conservative,' says B. Riley FBR
SCSC Scansource
$24.68 /

+0.03 (+0.12%)

ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

04/09/20 H.C. Wainwright
Zosano Pharma initiated with a Buy at H.C. Wainwright
11/15/19 BTIG
Zosano Pharma price target lowered to $16 from $19 at BTIG
11/15/19 Cantor Fitzgerald
Zosano Pharma price target lowered to $6 from $12 at Cantor Fitzgerald
ZSAN Zosano Pharma
$1.64 /

+0.03 (+1.86%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

TTOO T2 Biosystems
$1.56 /

+0.015 (+0.97%)

SITM SiTime
$66.03 /

-2.1 (-3.08%)

SCSC Scansource
$24.68 /

+0.03 (+0.12%)

RXT Rackspace Technology
$21.35 /

+2.045 (+10.59%)

NPTN NeoPhotonics
$6.67 /

-0.245 (-3.55%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

COHU Cohu
$17.19 /

-0.81 (-4.50%)

  • 01
    Sep
  • 05
    Aug
  • 12
    Jun
  • 21
    Nov
ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

RXT Rackspace Technology
$21.35 /

+2.045 (+10.59%)

NPTN NeoPhotonics
$6.67 /

-0.245 (-3.55%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

TTOO T2 Biosystems
$1.56 /

+0.015 (+0.97%)

RXT Rackspace Technology
$21.35 /

+2.045 (+10.59%)

NPTN NeoPhotonics
$6.67 /

-0.245 (-3.55%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

COHU Cohu
$17.19 /

-0.81 (-4.50%)

ZM Zoom Video
$325.24 /

+26.28 (+8.79%)

TTOO T2 Biosystems
$1.56 /

+0.015 (+0.97%)

RXT Rackspace Technology
$21.35 /

+2.045 (+10.59%)

KODK Eastman Kodak
$5.98 /

-0.055 (-0.91%)

GOGO Gogo
$5.15 /

+0.16 (+3.21%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.